The Effect of Pyridoxamine Supplementation on Microvascular Function in Type 2 Diabetes (PYRAMID)
Status
Conditions
Treatments
Details and patient eligibility
About
Patients with type 2 diabetes have an increased risk of developing vascular complications. Microvascular dysfunction might be caused by the increased production of methylglyoxal under hyperglycaemic conditions. Methylglyoxal is a by-product of glycolysis and forms advanced glycation endproducts (AGEs) on proteins and DNA, thereby disrupting their function. Preventing methylglyoxal accumulation and AGEs formation may offer a therapeutic option for treating microvascular complications in diabetics. Pyridoxamine is a vitamin B6 vitamer that scavenges methylglyoxal and thereby inhibits the formation of AGEs. In this study, the researchers investigate whether pyridoxamine supplementation in type 2 diabetes improves microvascular function in the eye, kidney and skin, and reduces markers of endothelial dysfunction and glycation.
Full description
Rationale:
People with diabetes have an increased risk of malfunctioning of the small blood vessels, e.g. in the eye and kidney, which can lead to blindness and kidney failure. These are serious complications, but to date there are no options to improve specifically the function of the small blood vessels. But why do people with diabetes have such an increased risk of dysfunction of the small blood vessels? The investigators have shown that a high glucose concentration in the blood plays an important role in the dysfunction of, particularly, the small blood vessels. A possible explanation for this dysfunction is an increased production of methylglyoxal, which arises from the breakdown of glucose. Methylglyoxal is a small but highly reactive molecule that can damage various organs and tissues. In several studies, the investigators found that methylglyoxal is increased in type 1 and type 2 diabetes and that methylglyoxal is associated with dysfunction of the smaller blood vessels. In our previous research in small laboratory animals, The investigators have shown that methylglyoxal directly causes damage of the small blood vessels. Because of these potentially harmful effects of methylglyoxal, the investigators have tried to reduce circulating methylglyoxal. In small laboratory animals, the investigators have found that the vitamin B6 isoform pyridoxamine inhibits the formation and accumulation of methylglyoxal, and improves vascular function. In a clinical trial in people with overweight, the investigators found that supplementation of pyridoxamine is safe and that methylglyoxal levels can be reduced, and the investigators found indications of an improvement of vascular function.
Objective:
Primary objective: to study whether pyridoxamine supplementation in type 2 diabetes improves microvascular function in the eye, kidney and skin, and reduces markers of endothelial dysfunction and glycation.
Secondary objective: to study whether pyridoxamine supplementation in type 2 diabetes improves glucose metabolism, advanced glycation endproduct (AGE) concentrations in blood plasma and skin, methylglyoxal, glyoxal and 3-deoxyglucose concentrations in blood plasma, adipokines and inflammatory markers in blood plasma, markers of dicarbonyl stress and oxidative stress in urine, liver fat, blood pressure, heart rate/ECG and body composition.
Study design:
The study will be conducted in a randomized, double blind, placebo-controlled manner. This intervention study includes two intervention periods of 8 weeks in a crossover design with a washout period of 4 weeks.
Study population:
Adult individuals (>18 years old) with type 2 diabetes, and with generalized microvascular dysfunction, i.e. an estimated glomerular filtration rate (eGFR) of 30-60 mL/min/1.73m2, and/or microalbuminuria of (albumin-creatinine ratio) 3-30 mg/mmol, and/or retinopathy (not proliferative), and/or neuropathy (any).
Intervention:
The daily dosage (300 mg) pyridoxamine or placebo will be supplied as three capsules of 100mg each per day, and are taken shortly before or during the meal.
Main study parameter:
The main study parameter is microvascular function in the eye, skin, plasma, and kidney measured by means of retinal funduscopy, adaptive optics funduscopy, optical coherence tomography (OCT), dynamic vessel analyser, skin laser doppler flowmetry, markers of endothelial function in the blood plasma, urinary albumin, and estimated glomerular filtration rate.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness:
The number of measurements during each visit in this study is quite substantial. Nonetheless, the investigators expect that the burden for the subjects is limited since all measurements, except blood withdrawal, are non-invasive, and are performed while sitting or in a supine, relaxed, and comfortable position. Additionally, potential benefits of participating in this study are directly related to the possible beneficiary effects of pyridoxamine as showed in a previous clinical trial. Moreover, pyridoxamine supplementation in this previous clinical trial did not result in serious adverse effects.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
-
Diagnosis of type 2 diabetes,
-
Generalized microvascular dysfunction, i.e.
- eGFR 30-60 mL/min/1.73m2, and/or
- Microalbuminuria albumin-creatinine ratio 3-30 mg/mmol, and/or
- Retinopathy (not proliferative), and/or
- Neuropathy (any).
Exclusion criteria
- Uncontrolled diabetes (i.e., hypoglycaemia >2 times/week and/or unstable HbA1c >9%),
- Use of >12 Units long-acting insulin per day,
- Use of short-acting insulin,
- Intraocular pressure ≥30 mmHg,
- History of glaucoma,
- Diagnosis of proliferative diabetic retinopathy,
- Diagnosis of diabetic macula edema,
- Albumine-creatinine ratio >30 mg/mmol,
- eGFR <30 mL/min/1.73m2,
- Diagnosis of epilepsy,
- Active cardiovascular disease,
- Alcohol usage >4 U/day,
- Drugs abuse,
- Use of systemic glucocorticosteroids,
- Higher grade hypertension
- Diagnosis of inflammatory disease,
- Use of an investigational product within the previous month,
- Unstable body weight,
- Pregnancy or lactation,
- Change in use of oral contraceptives or IUD,
- Unwillingness to give up being a blood donor (or having donated blood) from 8 weeks prior to the start of the study to end of study,
- Insufficient knowledge of the Dutch language,
- Inability to provide written informed consent.
Trial design
Primary purpose
Allocation
Interventional model
Masking
40 participants in 2 patient groups
Trial contacts and locations
Loading...
Central trial contact
M. van Oeteren, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal